Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

It was noted at Working Party meeting on the Treatment of Haemophiliacs that there was a shortfall of 3.5 million units of Factor 8 which it was agreed should be made up by commercial Factor 8.

  • Read more about It was noted at Working Party meeting on the Treatment of Haemophiliacs that there was a shortfall of 3.5 million units of Factor 8 which it was agreed should be made up by commercial Factor 8.

The return for 1984 showed for the Queen Elizabeth Hospital that there was predominantly treatment with NHS concentrate and Factorate in both hospital and home settings.

  • Read more about The return for 1984 showed for the Queen Elizabeth Hospital that there was predominantly treatment with NHS concentrate and Factorate in both hospital and home settings.

The Queen Elizabeth Hospital return for 1983 showed some treatment with cryoprecipitate in hospital but predominantly treatment with NHS concentrate and Factorate in both hospital and home settings.

  • Read more about The Queen Elizabeth Hospital return for 1983 showed some treatment with cryoprecipitate in hospital but predominantly treatment with NHS concentrate and Factorate in both hospital and home settings.

The Working Party meeting did not result in any change of approach in regards to cryoprecipitate.

  • Read more about The Working Party meeting did not result in any change of approach in regards to cryoprecipitate.

Dr Ala advised the West Midlands Working Party meeting - through letter - that cryoprecipitate was "probably a safer product than Factor VIII concentrate in respect of transmission of AIDS".

  • Read more about Dr Ala advised the West Midlands Working Party meeting - through letter - that cryoprecipitate was "probably a safer product than Factor VIII concentrate in respect of transmission of AIDS".

Professor Franklin described in a letter how he and Professor Hill took the view that patients should have continuity in their factor product and given how erratic the NHS supply was it was better to keep them on commercial Factor VIII than switch between the two when NHS product was available.

  • Read more about Professor Franklin described in a letter how he and Professor Hill took the view that patients should have continuity in their factor product and given how erratic the NHS supply was it was better to keep them on commercial Factor VIII than switch between the two when NHS product was available.

The UKHCDO recommended at the end of the 1983 meeting that patients did not switch from concentrates to cryo.

  • Read more about The UKHCDO recommended at the end of the 1983 meeting that patients did not switch from concentrates to cryo.

At a Committee on Safety of Medicines Sub-Committee on Biological Products meeting, it was stated that the cause of AIDS was unknown. It was postulated that a new agent may have beeen responsible, but repeated exposure to, or reactivation of, known agents, (e.g. CMV, EBV) may have beeen involved.

  • Read more about At a Committee on Safety of Medicines Sub-Committee on Biological Products meeting, it was stated that the cause of AIDS was unknown. It was postulated that a new agent may have beeen responsible, but repeated exposure to, or reactivation of, known agents, (e.g. CMV, EBV) may have beeen involved.

Figures relating to the annual consumption of commercial factor concentrate at different haemophilia centres between 1976 and 1994. Also included are the factor types, product names, haemophilia type, number of units and volume amounts.

  • Read more about Figures relating to the annual consumption of commercial factor concentrate at different haemophilia centres between 1976 and 1994. Also included are the factor types, product names, haemophilia type, number of units and volume amounts.

In Glasgow Royal Infirmary, the 77 patients whose blood was tested for HIV as part of a study were not told that these tests were taking place.

  • Read more about In Glasgow Royal Infirmary, the 77 patients whose blood was tested for HIV as part of a study were not told that these tests were taking place.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 38
  • Page 39
  • Page 40
  • Page 41
  • Current page 42
  • Page 43
  • Page 44
  • Page 45
  • Page 46
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.